The 34th Annual Meeting of
the Asian Pacific Association for the Study of the Liver

APASL 2025 BEIJING

Multidisciplinary Collaboration For Elimination & Cure

26-30 March 2025 | China National Convention Center Beijing

State-of-The-Art lecture
(28th Mar 2025)

From Hepatitis to Liver Cancer

George Lau

MBBS (HKU), M.D. (HKU), FRCP (Edin, Lond), FHKAM (Med), FHKCP, FAASLD (USA)

info@apasl2025beijing.com

www.apasl2025beijing.com

Research interest

- Immunotherapy in liver diseases

Selected awards

- Royal Society Award (UK) - 1998
- Ten Most Outstanding Young Persons 2002 (HKSAR) - 2002
- HKU Medical Faculty Outstanding Research Output Award - 2006
- National Science and Technology Progress Award (State Science and Technology Prizes) - Technological advancement in Chronic hepatitis B infection management - 2015
- Chief Executive's Commendation for government service -2022
- APASL Okuda-Omata Distinguished Award - 2023

Academic output

- Publications: 300+, Citations: 47,000+, H-index: 98 (source: google scholar until Feb 2025)
- First/corresponding author for original articles in NEJM, Lancet, Lancet GH, Gastroenterology, J Hepatol, Hepatology, Hepatol Int, NEJM Evid, et al

Disclosure of Conflict of Interest

Consulting or advisory role

AstraZeneca, Biegene

Leadership

- Chairman and Senior Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Group
- Independent Non-Executive Director, JD Health International Inc
- Chair Professor and Senior Consultant, Zhongshan Hospital, Fudan University, *Shanghai 200032,* China
- Distinguished Professor, Shulan International Medical College, Hangzhou, Zhejiang Province, China
- Visiting Professor, Qingdao University, Shandong Province, China
- Senior Member of Steering Committee, Asian Pacific Association for the Study of the Liver (APASL)
- Executive Member, Board of Directors, Asian-Pacific Digestive Week Federation (APDWF)
- HKU Foundation board member

Perspective from a practicing academic hepatologist in Asia



My journey as an academic hepatologist in China

From 1990 till now and beyond

Late Professor Sir David Todd (1928-2017)

Intellectual growth should commence at birth and cease only at death



Two and half decades ago……..

Hepatitis Free Generation

世代無肝炎


国际候机厅


A31 採射燈
東方日報
2001年12月4日 星期二
採射燈
捐50元救內地貧困嬰
遠離肝炎

Clinical Practice Changing original publications

Hepatitis B reactivation (HBVr)

Anti-viral therapy

- Hepatitis B virus (HBV)
- Hepatitis C virus (HCV)

Hepatocellular carcinoma (HCC)

With Late Professor Roger Williams

- **“We know what we are, but know not what we may be.”**
- William Shakespeare

Hepatitis B reactivation (HBVr)

HBVr remains a major cause of ACLF

Hepatology International (2019) 13:353–390
https://doi.org/10.1007/s12072-019-09946-3

GUIDELINES

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

Shiv Kumar Sarin[1] · Ashok Choudhury[1] · Manoj K. Sharma[1] · Rakhi Maiwall[1] · Mamun Al Mahtab[2] · Salimur Rahman[2] · Sanjiv Saigal[3] · Neeraj Saraf[3] · A. S. Soin[3] · Harshad Devarbhavi[4] · Dong Joon Kim[5] · R. K. Dhiman[6] · Ajay Duseja[6] · Sunil Taneja[6] · C. E. Eapen[7] · Ashish Goel[7] · Q. Ning[8] · Tao Chen[9] · Ke Ma[8] · Z. Duan[9] · Chen Yu[9] · Sombat Treeprasertsuk[10] · S. S. Hamid[11] · Amna S. Butt[11] · Wasim Jafri[11] · Akash Shukla[12] · Vivek Saraswat[13] · Soek Siam Tan[14] · Ajit Sood[15] · Vandana Midha[15] · Omesh Goyal[15] · Hasmik Ghazinyan[16] · Anil Arora[17] · Jinhua Hu[18] · Manoj Sahu[19] · P. N. Rao[20] · Guan H. Lee[21] · Seng G. Lim[21] · Laurentius A. Lesmana[22] · Cosmas Rinaldi Lesmana[22] · Samir Shah[23] · V. G. Mohan Prasad[24] · Diana A. Payawal[25] · Zaigham Abbas[26] · A. Kadir Dokmeci[27] · Jose D. Sollano[28] · Gian Carpio[28] · Ananta Shresta[29] · G. K. Lau[30] · Md. Fazal Karim[31] · Gamal Shiha[32] · Rino Gani[33] · Kemal Fariz Kalista[33] · Man-Fung Yuen[34] · Seema Alam[35] · Rajeev Khanna[35] · Vikrant Sood[35] · Bikrant Bihari Lal[35] · Viniyendra Pamecha[36] · Ankur Jindal[1] · V. Rajan[1] · Vinod Arora[1] · Osamu Yokosuka[37] · Madunil A. Niriella[38] · Hai Li[39] · Xiaolong Qi[40] · Atsushi Tanaka[41] · Satoshi Mochida[42] · Dominic Ray Chaudhuri[43] · Ed Gane[43] · Khin Maung Win[44] · Wei Ting Chen[45] · Mohd. Rela[46] · Dharmesh Kapoor[23] · Amit Rastogi[3] · Pratibha Kale[47] · Archana Rastogi[48] · Chhagan Bihari Sharma[48] · Meenu Bajpai[49] · Virender Singh[6] · Madhumita Premkumar[6] · Sudhir Maharashi[50] · A. Olithselvan[51] · Cyriac Abby Philips[52] · Anshu Srivastava[53] · Surender K. Yachha[53] · Zeeshan Ahmad Wani[54] · B. R. Thapa[55] · Anoop Saraya[56] · Shalimar[56] · Ashish Kumar[17] · Manav Wadhawan[57] · Subash Gupta[58] · Kaushal Madan[59] · Puja Sakhuja[60] · Vivek Vij[61] · Barjesh C. Sharma[62] · Hitendra Garg[63] · Vishal Garg[63] · Chetan Kalal[64] · Lovkesh Anand[65] · Tanmay Vyas[66] · Rajan P. Mathur[67] · Guresh Kumar[68] · Priyanka Jain[68] · Samba Siva Rao Pasupuleti[68] · Yogesh K. Chawla[69] · Abhijit Chowdhury[70] · Shahinul Alam[2] · Do Seon Song[71] · Jin Mo Yang[71] · Eileen L. Yoon[72] · APASL ACLF Research Consortium (AARC) for APASL ACLF working Party.

(Citation-819)

GASTROENTEROLOGY 2003;125:1742–1749

Early Is Superior to Deferred Preemptive Lamivudine Therapy for Hepatitis B Patients Undergoing Chemotherapy

GEORGE K. K. LAU,* HARRY H. Y. YIU,† DANIEL Y. T. FONG,§ HOI–CHING CHENG,† WING–YAN AU,‖ LYDIA S. F. LAI,* MICHEAL CHEUNG,† HAI–YING ZHANG,* ALBERT LIE,‖ ROGER NGAN,† and RAYMOND LIANG‖

*Division of Gastroenterology and Hepatology; †Department of Clinical Oncology; and §Clinical Trials Centre and ‖Division of Hematology, University Department of Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, China

(Citation - 588)

First randomized controlled trial (RCT) which laid the foundation on the use of pre-emptive anti-HBV NUCs in HBV-infected patients treated with immunosuppressive therapy for prevention of liver-related morbidity and mortality due to HBVr



Survival free from hepatitis due to HBVr in HBsAg+ lymphoma patients who received intense chemotherapy and were treated with early (group 1, -●-●) and deferred (group 2, -0-0)) pre-emptive lamivudine therapy

Lau G, et al. Gastroenterology 2003; 125:1742-49.

Clinical Gastroenterology and Hepatology 2017;15:132–136

Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents

Cheng Wang,[*,‡] Dong Ji,[§,‖] Jing Chen,[*] Qing Shao,[§] Bing Li,[§] Jialiang Liu,[§] Vanessa Wu,[*] April Wong,[*] Yudong Wang,[*] Xiaoyong Zhang,[‡] Lei Lu,[*] Chris Wong,[¶] Stella Tsang,[¶] Zheng Zhang,[#] Jian Sun,[‡] Jinlin Hou,[‡] Guofeng Chen,[§] and George Lau[*,§,#]

[*]Division of Gastroenterology and Hepatology, Humanity and Health Medical Centre, Hong Kong SAR, China; [‡]State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; [§]Second Liver Cirrhosis Diagnosis and Treatment Center, 302 Hospital, Beijing, China; [‖]Liver Failure Treatment and Research Centre, 302 Hospital, Beijing, China; [¶]Hong Kong Molecular Pathology Diagnostic Centre, Hong Kong SAR, China; and [#]Institute of Translational Hepatology, 302 Hospital, Beijing, China

(Citation-249)

First single cohort study which demonstrate the occurrence of hepatitis due to HBV reactivation in HBV-HCV coinfected patients treated with DAAs. This led the US FDA EMA to issue a “black- box” warning which change the DAAs management algorithm in HCV patients



Wang et al. Clin Gastroentrol Hepatol 2017, 15:132-136

Hepatology International (2021) 15:1031–1048
https://doi.org/10.1007/s12072-021-10239-x

GUIDELINES

APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

George Lau[1,2] · Ming-Lung Yu[3] · Grace Wong[4] · Alexander Thompson[5] · Hasmik Ghazinian[6] · Jin-Lin Hou[7] · Teerha Piratvisuth[8] · Ji-Dong Jia[9] · Masashi Mizokami[10] · Gregory Cheng[2,11] · Guo-Feng Chen[12] · Zhen-Wen Liu[13] · Oidov Baatarkhuu[14] · Ann Lii Cheng[15] · Woon Leung Ng[16] · Patrick Lau[1] · Tony Mok[17] · Jer-Ming Chang[18] · Saeed Hamid[19] · A. Kadir Dokmeci[20] · Rino A. Gani[21] · Diana A. Payawal[22] · Pierce Chow[23] · Joong-Won Park[24] · Simone I. Strasser[25] · Rosmawaiti Mohamed[26] · Khin Maung Win[27] · Tanwandee Tawesak[28] · Shiv Kumar Sarin[29] · Masao Omata[30,31]

Citation-127



* If ALT increase is >2x baseline, check HBsAg, HBV DNA and start NUCs treatment for patients with HBsAg sero-reversion or > 2 log increase in HBV DNA.

Lau G, et al. Hepatol Int. 2021;15(5):1031-1048.

Anti-viral therapy HBV and HCV

Global phase 3 clinical trials which led to the registration of pegylated interferon-a2a as a form of treatment for CHB infection

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

Patrick Marcellin, M.D., George K.K. Lau, M.D., Ferruccio Bonino, M.D., Patrizia Farci, M.D., Stephanos Hadziyannis, M.D., Rui Jin, M.D., Zhi-Meng Lu, M.D., Teerha Piratvisuth, M.D., Georgios Germanidis, M.D., Cihan Yurdaydin, M.D., Moises Diago, M.D., Selim Gurel, M.D., Ming-Yang Lai, M.D., Peter Button, M.Sc., and Nigel Pluck, M.D., for the Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group*

N Engl J Med. 2004; 16;351(12):1206-17.

(**Citation-1545**)

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

George K.K. Lau, M.D., Teerha Piratvisuth, M.D., Kang Xian Luo, M.D., Patrick Marcellin, M.D., Satawat Thongsawat, M.D., Graham Cooksley, M.D., Edward Gane, M.D., Michael W. Fried, M.D., Wan Cheng Chow, M.D., Seung Woon Paik, M.D., Wen Yu Chang, M.D., Thomas Berg, M.D., Robert Flisiak, M.D., Philip McCloud, Ph.D., and Nigel Pluck, M.D., for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group*

N Engl J Med. 2005;352(26):2682-95.

(**Citation-2049**)

Drug	CHB	Primary Endpoint	Publications
LAM	HBeAg+/-	> two points in ↓Knodell NI score	Lai CL NEJM 1998
ADV	HBeAg+	> two points in ↓Knodell NI score*	Marcellin P NEJM 2003
	HBeAg-	> two points in ↓Knodell NI score*	Hadziyannis SJ NEJM 2003
pIFNα2a	HBeAg+	HBeAg seroconversion Serum HBV DNA < 10^5 copies/ml	Lau G NEJM 2005
	HBeAg-	normalization of ALT; HBV DNA <20,000 copies/ml	Marcellin P NEJM 2003
LDT	HBeAg+/-	serum HBV DNA <5 $\log_{10}$ copies/ml; loss of HBeAg normalization of ALT	Lai CL NEJM 2007
TDF	HBeAg+/-	HBV DNA< 400 copies/ml > two points in ↓Knodell NI score*	Marcellin P NEJM 2008
ETV	HBeAg-	> two points in ↓Knodell NI score*	Lai CL NEJM 2006
	HBAg+	> two points in ↓Knodell NI score*	Chang TT NEJM 2006
CLV	HBeAg+	HBV DNA < 300 copies/mL; HBeAg seroconversion	Lau G Korean J Hepatol 2009
TAF	HBeAg+	HBV DNA< 29 IU/mL	Chan HL Lancet GH 2016
	HBeAg-	HBV DNA< 29 IU/mL	Buti M Lancet GH 2016

*with no worsening of Knodell fibrosis score

Anti-HBV drug approved by 2016

Humanity & Health

Faculty Members and Participants of Asian Pacific Consensus for Diagnosis and Treatment of Chronic Hepatitis B and C, Kyoto, Japan, 6-7 September 1999

(Back row from left to right) J Lau , M Robertson, J McDonald, P Desmond, C Hum, Y Shiratori, J Fawcett, KC Tan, K Preston, E Tanaka, BE Wang, J Humphries, A Yan, M Preston (3rd row from left to right) J Kaldor, J Chen, ST Fan, NH Stace, E Gane, M Zeniya, O Yokosuka, GKK Lau, H Furukawa, CL Lai , K Tanaka (2nd row from left to right) M. Sinclair, H Yatsuhashi, A Chutaputti, R Guan, I Merican, K Shiraki, J-H Kao, GB Yao (1st row from left to right) C-M Chu, M Atkins, C-J Chen, M-Y Lai, WC Chow, D-S Chen, M Yano, K Okuda, G Farrell, Y-F L

Hepatol Int (2016) 10:1–98
DOI 10.1007/s12072-015-9675-4

GUIDELINES

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

S. K. Sarin[1] · M. Kumar[1] · G. K. Lau[2,27] · Z. Abbas[3] · H. L. Y. Chan[4] · C. J. Chen[5] · D. S. Chen[6] · H. L. Chen[7] · P. J. Chen[8] · R. N. Chien[9] · A. K. Dokmeci[10] · Ed Gane[11] · J. L. Hou[12] · W. Jafri[13] · J. Jia[14] · J. H. Kim[15] · C. L. Lai[16] · H. C. Lee[17] · S. G. Lim[18] · C. J. Liu[7] · S. Locarnini[19] · M. Al Mahtab[20] · R. Mohamed[21] · M. Omata[22] · J. Park[23] · T. Piratvisuth[24] · B. C. Sharma[25] · J. Sollano[26] · F. S. Wang[28] · L. Wei[29] · M. F. Yuen[30] · S. S. Zheng[31] · J. H. Kao[32]

Received: 20 May 2015 / Accepted: 14 September 2015 / Published online: 13 November 2015

(Citation-2860)

Current guidelines on eligibility for antiviral treatment in CHB patients

Limitations

- New/more sensitive biomarkers-qHBsAg, rHBcAg, HBV RNA, HBV DNA
- Non-invasive liver fibrosis assessment
- Co-morbidity factor-MAFLD

NR-nor required; *IU/ml

Guidelines	No liver cirrhosis						Cirrhosis	
	HBeAg+			HBeAg-				
	HBV DNA*	Serum ALT	Histology	HBV DNA*	Serum ALT	Histology	Compensated	Decompensated
AASLD[1]	>20,000	≥2 x ULN	NR	≥2000	≥2XULN	NR	HBV DNA+	ALL
	>20,000	1-2X ULN	≥F2 or ≥A2	>2000	>ULN	≥F2 or ≥A2		
APASL[2]	>20,000	≥2 x ULN	NR	>2000	>ULN	NR	HBV DNA*>2000 /HBV DNA+ALT>ULN	HBV DNA+
	>20,000	1-2xULN	≥F2 or ≥A2	>2000	≥2XULN	≥F2 or ≥A2		
EASL[3]	>20,000	>2xULN	NR	>20,000	>2xULN	NR	HBV DNA+	
	>2000	>ULN	≥F2 or ≥A2	>2000	>ULN	≥F2 or ≥A2		

[1]*Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance. Hepatology 67, 1560–1599 (2018).*
[2]*Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10, 1–98 (2016).*
[3]*European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370–398 (2017).*

CHB
“Functional CURE”

Humanity & Health

Definition of “Cure”

Therapy

↓

Loss of HBsAg

↓

Sustained off-therapy disease remission

- To make someone with an illness healthy again
  - Cambridge dictionary
- To make a person healthy again after an illness
  - Oxford learner dictionary

Functional “Cure”- current registered anti-HBV therapy

Monotherapy

- pIFNα2a x 48 wks:3-8 %

  Lau 2005, Marcellin 2004

- High-resistant barrier NUCs:<1%/yr

Combination therapy

- De novo: 1-15% at wk 24-720

  Ahn 2018, Yim 2020, Lok 2011, Hagiwara 2018, Zheng 2019

- Add-on:1-11% at wk48-226

  Jindal 2018, Bouriliere 2017, Van Campenhout 2019, Li 2015

- Switch:1-33% at wk 48-72

  Ning 2014, Hsu 2018, Yoshida 2021, Lim 2020

96-week pIFNα2a to CHB on NUCs

HBcrAg <4 log10U/ml and HBsAb >2 log10IU/L at EOT

PPV -100% for SVR with an AUROC of 0.822 (0.684-0.961, p = 0.001)

257 CHB on NUCS (1-5 yrs) with serum HBV DNA <−1,000 copies/ ml and HBsAg <−3,000 IU/ml (ANCHOR)

↓

80 randomly assigned to 96-week p-IFN-a-based Rx with 24-week off-Rx FU

↓

21 (26.3%) sustained HBsAg loss (SVR)

Huang D et al J Hepatol. 2022;77(1):42-54.

Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis

Chen J, Ji D, Jia JD, Zhuang H, Zhang X, Wang FS, Zhang WH, Dou XG, Tanwandee T, Sarin SK, Maiwall R, Kumar M, Goh GBB, Hasmik G, Chutaputti A, Chen PJ, You H, Yu ML, George J, Omata M, Wang GQ, Lau G* , On behalf of APASL Viral Elimination Taskforce

Chen J Hepatol Int 2025 (in press)



Reported rate of functional cure by compounds categories.

Rate of functional cure- very low

Though numerically higher, rate in ASO was not statistically significant than that in CAM (p=0.81) and siRNA (p=0.35)

P values were estimated by meta regression

Chen J Hepatol Int 2025 (in press)

Decline In HBsAg Level-not durable





HBsAg change from baseline measured at (A) EOT and (B) EOF in those with reported decline (negative change). Among the five studies with both reported negative on-tx and off-tx change from baseline (contributing to 26 unique treatment arms), the pooled on-tx decline from baseline was -1.20 log10 IU/mL (95%CI -1.44 to -0.96, $p<0.001$, $I^2=99.5\%$) while the pooled off-tx decline from baseline was -0.64 log10 IU/mL (95%CI -0.73 to -0.56, $p<0.001$, $I^2=98.6\%$).

Revelation of unknown confounding factor (group 3) impeded functional "cure" for CHB

No clear Dose-Dependent-phase 2b study

CHB on NUCs with HBsAg reduction ≥3 log10 IU/mL at wk 12

Gp 3 (16%) vs Gp1 (34%, p=0.01) vs Gp 2 (37%, p=0.005)

Figure S3. Proportion of Participants (A) Receiving NA Therapy and (B) Not Receiving NA Therapy, Achieving the Primary Outcome by Baseline HBeAg and HBsAg status (ITT Population).



Figure S11. Categorical Changes from Baseline in HBsAg (i.e., reductions of <0.5, ≥0.5–<1, ≥1–<1.5, ≥1.5–<3, ≥3 log10 IU/mL) in (A) Participants Receiving NA Therapy and (B) Participants Not Receiving NA Therapy (ITT Population).



GSK B-Clear study NEJM 2022

Xalnesiran for CHB

Xalnesiran- siRNA molecule that targets a conserved region of the HBV genome and silences multiple HBV transcripts



Abbreviations: CpAM= core protein allosteric modulator; EOT=end-of-treatment; HBsAg=Hepatitis B surface antigen; NME= new molecular entity; NUC= nucleos(t)ide; TLR7=toll-like receptor 7; TBD=to be determined.

* Initially 30 participants. Approximately 5 additional participants per future treatment arm will be randomized to the control arm.



HBsAg loss

- Only in participants with baseline HBsAg <1000 IU/mL
- Need the addition of Peg-IFN

Hou J, et al. N Engl J Med. 2024 Dec 5;391(22):2098-2109.

Major considerations for new drug development- compared with existing therapy (p-IFN/NUCs)

- SAFETY
- EFFICACY
- COST
- UNKNOWN CONFOUNDING FACTOR

Importance of immunity to “cure” liver diseases

GASTROENTEROLOGY 2002;122:614–624

CLINICAL RESEARCH

Resolution of Chronic Hepatitis B and Anti-HBs Seroconversion in Humans by Adoptive Transfer of Immunity to Hepatitis B Core Antigen

GEORGE K. K. LAU,*,† DEEPAK SURI,* RAYMOND LIANG,† EIRINI I. RIGOPOULOU,* MARK G. THOMAS,§ IVANA MULLEROVA,* AMIN NANJI,‖ SIU–TSAN YUEN,‖ ROGER WILLIAMS,* and NIKOLAI V. NAOUMOV*

*Institute of Hepatology and §Department of Biology, University College London, London, England; and Departments of †Medicine and ‖Pathology, Queen Mary Hospital, Hong Kong, China

(Citation-237)

This study demonstrate the importance of restoration of immune response to chronic hepatitis B is required for a "CURE"







Lau G, et al. Gastroenterology 2002;122: 614-624.

HCC

Immune checkpoint inhibitors (ICIs) as cancer immunotherapy





Nature 562, 20-21 (2018)

Research Article
Hepatic and Biliary Cancer

JOURNAL
OF HEPATOLOGY

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

George Lau[1,†], **Ghassan K. Abou-Alfa**[2,3,*,†], Ann-Lii Cheng[4], Wattana Sukeepaisarnjaroen[5], Tu Van Dao[6], Yoon Koo Kang[7], Satheesh Chiradoni Thungappa[8], Masatoshi Kudo[9], Bruno Sangro[10], Robin Kate Kelley[11], Junji Furuse[12], Joong-Won Park[13], Patrapim Sunpaweravong[14], Angelica Fasolo[15], Thomas Yau[16], Tomokazu Kawaoka[17], Sergio Azevedo[18], Maria Reig[19], Eric Assenat[20], Mark Yarchoan[21], Aiwu Ruth He[22], Mallory Makowsky[23,‡], Charu Gupta[24], Alejandra Negro[23], **Stephen L. Chan**[25,†]

Lau G, et al. J Hepatol. 2025;82(2):258-267.

First Asian study to demonstrate the benefits of STRIDE for HCC patients in the Asia-Pacific region



479 participants in the Asia-Pacific region

Randomisation

STRIDE (n = 156)
Durvalumab (n = 167)
Sorafenib (n = 156)

Overall survival (OS) was improved for **STRIDE** *vs.* **sorafenib** (HR 0.68; 95% CI 0.52-0.89)

The **OS** HR for **durvalumab** *vs.* **sorafenib** was 0.83 (95% CI 0.64-1.06)



Grade 3/4 treatment-related adverse events were numerically lower for **STRIDE** (19.9%) and **durvalumab** (13.3%) *vs.* **sorafenib** (30.5%)

STRIDE improved outcomes versus sorafenib in the Asian subgroup.
These results support the benefits of STRIDE for participants with unresectable hepatocellular carcinoma globally, including the Asia-Pacific region.

Lau G, et al. J Hepatol. 2025;82(2):258-267.

Hepatology International
https://doi.org/10.1007/s12072-024-10732-z

GUIDELINES

APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024

George Lau[1] · Shuntaro Obi[2] · Jian Zhou[3] · Ryosuke Tateishi[4] · Shukui Qin[5] · Haitao Zhao[6] · Motoyuki Otsuka[7] · Sadahisa Ogasawara[8] · Jacob George[9] · Pierce K. H. Chow[10] · Jianqiang Cai[11] · Shuichiro Shiina[12] · Naoya Kato[13] · Osamu Yokosuka[14] · Kyoko Oura[15] · Thomas Yau[16] · Stephen L. Chan[17] · Ming Kuang[18] · Yoshiyuki Ueno[19] · Minshan Chen[20] · Ann-Lii Cheng[21] · Gregory Cheng[22,58] · Wan-Long Chuang[23] · Oidov Baatarkhuu[24] · Feng Bi[25] · Yock Young Dan[26] · Rino A. Gani[27] · Atsushi Tanaka[28] · Wasim Jafri[29] · Ji-Dong Jia[30] · Jia-Horng Kao[31] · Kiyoshi Hasegawa[32] · Patrick Lau[33] · Jeong Min Lee[34] · Jun Liang[35] · Zhenwen Liu[36] · Yinying Lu[37] · Hongming Pan[38] · Diana A. Payawal[39] · Salimur Rahman[40] · Jinsil Seong[41] · Feng Shen[42] · Gamal Shiha[43,59,60,61] · Tianqiang Song[44] · Hui-Chuan Sun[45] · Tsutomu Masaki[15] · Ekaphop Sirachainan[46] · Lai Wei[47] · Jin Mo Yang[48] · Jose D. Sallano[49] · Yanqiao Zhang[50] · Tawesak Tanwandee[51] · AKadir Dokmeci[52] · Shu-sen Zheng[53] · Jia fan[54] · Sheung-Tat Fan[55] · Shiv Kumar Sarin[56] · Masao Omata[57]

Treatment Algorithm of HCC (APASL 2024)



Lau G, et al. Hepatol Int. 2024;18(6):1661-1683.

Take home messages

CHB

- Functional cure-need addition of immunomodulatory therapy

CHC

- CURE

HCC

- ICIs-based therapy

Our team

In loving memory our wonderful colleague-Professor Dr. dr. Laurentius A. Lesmana, Sp. PD-KGEH